Xadago (Safinamide Mesylate) Patent Expiration, LOE Window & CMS Spending
Xadago (Safinamide Mesylate) by Mdd Us Operations: FDA Orange Book core substance LOE 2028-12-10 (last listed 2031-03-21), 3 AB generics, $7.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Mdd Us Operations |
| FDA Application & Pathway | N207145 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2028-12-10 |
| Last Listed Patent or Exclusivity Date | 2031-03-21 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $7.9M |
| 2024 Medicare Part D Spend | $7.7M |
| 2024 Medicaid Spend | $270K |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 26.0% 2-yr change) |